Evidence map›Paper›PMID 37511684›Full record

ArticleJournal of personalized medicine2023

Pancreas Rejection in the Artificial Intelligence Era: New Tool for Signal Patients at Risk.

Emanuel Vigia, Luís Ramalhete, Rita Ribeiro, Inês Barros, Beatriz Chumbinho, Edite Filipe, Ana Pena, Luís Bicho, Ana Nobre, Sofia Carrelha and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Emanuel VigiaHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.ORCID 0000-0002-4525-9062
Luís RamalheteNova Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal.ORCID 0000-0002-8911-3380
Rita RibeiroNova Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal.
Inês BarrosHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
Beatriz ChumbinhoHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
Edite FilipeHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
Ana PenaHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
Luís BichoHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
Ana NobreHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
Sofia CarrelhaHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
Mafalda SobralHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
Jorge LamelasHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
João Santos CoelhoHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.
Aníbal FerreiraiNOVA4Health, Advancing Precision Medicine, RG11, Reno-Vascular Diseases Group, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal.
Hugo Pinto MarquesHepatobiliopancreatic and Transplantation Center, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, R. da Beneficência 8, 1050-099 Lisbon, Portugal.ORCID 0000-0003-3540-0488
Hospital Curry Cabral · PTInstituto Portugues do Sangue e da Transplantacao, IP · PTUniversidade Nova de Lisboa · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPancreas transplantation is currently the only treatment that can re-establish normal endocrine pancreatic function. Despite all efforts, pancreas allograft survival and rejection remain major clinical problems. The purpose of this study was to identify features that could signal patients at risk of pancreas allograft rejection.

methodsWe collected 74 features from 79 patients who underwent simultaneous pancreas-kidney transplantation (SPK) and used two widely-applicable classification methods, the Naive Bayesian Classifier and Support Vector Machine, to build predictive models. We used the area under the receiver operating characteristic curve and classification accuracy to evaluate the predictive performance via leave-one-out cross-validation.

resultsRejection events were identified in 13 SPK patients (17.8%). In feature selection approach, it was possible to identify 10 features, namely: previous treatment for diabetes mellitus with long-term Insulin (U/I/day), type of dialysis (peritoneal dialysis, hemodialysis, or pre-emptive), de novo DSA, vPRA_Pre-Transplant (%), donor blood glucose, pancreas donor risk index (pDRI), recipient height, dialysis time (days), warm ischemia (minutes), recipient of intensive care (days). The results showed that the Naive Bayes and Support Vector Machine classifiers prediction performed very well, with an AUROC and classification accuracy of 0.97 and 0.87, respectively, in the first model and 0.96 and 0.94 in the second model.

conclusionOur results indicated that it is feasible to develop successful classifiers for the prediction of graft rejection. The Naive Bayesian generated nomogram can be used for rejection probability prediction, thus supporting clinical decision making.

Indexed as

allograft rejectionallograft survivalartificial intelligencemachine learningpancreas transplantationpatient risk management

Identifiers

PMID37511684
PMCPMC10381793
OpenAlexW4382809635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.